GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac ...

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager, from ...

With Donald Trump now poised to become U.S. president for the second time in January, biotech and pharmaceutical leaders are preparing for the shift to an administration with a complicated history.

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... growth by minus 8% this quarter, meaning underlying operating profit was ...

On Monday, GSK plc (NYSE:GSK) released headline results ... nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52. Also Read: GSK’s Asthma ...

GSK’s blockbuster hopes for depemokimab remain ... the total endoscopic nasal polyp score at 52 weeks as well as the mean nasal obstruction score from weeks 49 to 52. GSK is saving detailed ...